Cambridge Nutritional Sciences (FRA:RVKA) Research & Development: €0.00 Mil (TTM As of Sep. 2025)


What is Cambridge Nutritional Sciences Research & Development?

Cambridge Nutritional Sciences FRA:RVKA Research & Development is €0.00 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cambridge Nutritional Sciences's Research & Development for the six months ended in Sep. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was €0.00 Mil.

Cambridge Nutritional Sciences  (FRA:RVKA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cambridge Nutritional Sciences Research & Development Related Terms

Cambridge Nutritional Sciences Research & Development Historical Data

* Premium members only.

The historical data trend for Cambridge Nutritional Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambridge Nutritional Sciences Research & Development Chart

Cambridge Nutritional Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cambridge Nutritional Sciences Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cambridge Nutritional Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a Research & Development of €0.00 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on Cambridge Nutritional Sciences and its competitors.
Is Cambridge Nutritional Sciences' Research & Development too high?
Cambridge Nutritional Sciences' current Research & Development is €0.00 Mil.
How does Cambridge Nutritional Sciences' Research & Development compare to ISRG and BDX?
Cambridge Nutritional Sciences' Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cambridge Nutritional Sciences and its competitors. Cambridge Nutritional Sciences's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Possible Value Trap. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 32.5% below its estimated fair value. The current Research & Development is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current Research & Development is €0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges CNSL:UK
Address One Fleet Place, London, GBR, EC4M 7WS
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.